Skip to main content
Clinical Trials/NCT05430763
NCT05430763
Withdrawn
N/A

Motor Deficits and Signal Conduction in Individuals With Williams Syndrome

Sheba Medical Center1 site in 1 countryFebruary 2023

Overview

Phase
N/A
Intervention
Not specified
Conditions
Williams Syndrome
Sponsor
Sheba Medical Center
Locations
1
Primary Endpoint
Nerve conduction test - Amplitude
Status
Withdrawn
Last Updated
last year

Overview

Brief Summary

The current study aims to validate basic research findings of abnormal conductivity and motor abilities from a mouse model in humans. The study will measure nerve conduction properties in WS individuals and characterize motor symptoms in individuals with WS.

Detailed Description

50 individuals with WS will take part in the study. All participants will be recruited from the Williams Syndrome Clinic at Edmond and Lili Safra Children's Hospital, Sheba Medical Center directed by Prof. Doron Gothelf, MD, that coordinates treatment and research of WS in Israel. 20 control age-matched subjects will be recruited as well. A Motor Questionnaire, designed especially for this study will be filled by parents. It includes questions about gross motor, fine motor, gait and coordination characteristics of the children (Bellugi, Bihrle et al. 1990, Wilson, Kaplan et al. 2000, Wilson, Crawford et al. 2009) (General references regarding motor abilities and health). In addition, participants will undergo the following assessments at the neuromuscular clinic and at the movement laboratory, Sheba Medical Center in collaboration with Dr. Amir Dori, Dr. Uri Givon and Dr. Meir Plotnik: (1) nerve conduction study (2) nerve ultrasound (3) neurological assessments (4) GAITRite walkway for gait analysis (5) 3-D motion analysis.

Registry
clinicaltrials.gov
Start Date
February 2023
End Date
August 2030
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • WS patients.

Exclusion Criteria

  • WS patients suffering from additional neurological condition (such as epilepsy).
  • Participants who will have difficulties preforming the tests may ask to be excluded.

Outcomes

Primary Outcomes

Nerve conduction test - Amplitude

Time Frame: 30 days

This test's amplitude outcome present a nerve conduction property that can indicate aberrations in signal conduction.

Nerve conduction test - Latency

Time Frame: 30 days

This test's latency outcome present a nerve conduction property that can indicate aberrations in signal conduction.

Study Sites (1)

Loading locations...

Similar Trials